176 related articles for article (PubMed ID: 32266538)
21. Correlation of SHOX2 gene amplification and DNA methylation in lung cancer tumors.
Schneider KU; Dietrich D; Fleischhacker M; Leschber G; Merk J; Schäper F; Stapert HR; Vossenaar ER; Weickmann S; Liebenberg V; Kneip C; Seegebarth A; Erdogan F; Rappold G; Schmidt B
BMC Cancer; 2011 Mar; 11():102. PubMed ID: 21426551
[TBL] [Abstract][Full Text] [Related]
22. A Novel Diagnosis Method Based on Methylation Analysis of SHOX2 and Serum Biomarker for Early Stage Lung Cancer.
Huang W; Huang H; Zhang S; Wang X; Ouyang J; Lin Z; Chen P
Cancer Control; 2020; 27(1):1073274820969703. PubMed ID: 33167712
[TBL] [Abstract][Full Text] [Related]
23. A prediction model based on DNA methylation biomarkers and radiological characteristics for identifying malignant from benign pulmonary nodules.
Xing W; Sun H; Yan C; Zhao C; Wang D; Li M; Ma J
BMC Cancer; 2021 Mar; 21(1):263. PubMed ID: 33691657
[TBL] [Abstract][Full Text] [Related]
24. RASSF1A is not appropriate as an early detection marker or a prognostic marker for non-small cell lung cancer.
Choi N; Son DS; Song I; Lee HS; Lim YS; Song MS; Lim DS; Lee J; Kim H; Kim J
Int J Cancer; 2005 Jul; 115(4):575-81. PubMed ID: 15700308
[TBL] [Abstract][Full Text] [Related]
25. [DNA methylation detection of SHOX2 and PTGER4 in plasma contributes to differential diagnosis of pulmonary nodule patients].
Chu X; Zhao W; Wang B
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2019 Apr; 35(4):357-361. PubMed ID: 31167696
[TBL] [Abstract][Full Text] [Related]
26. miR-375 Combined with SHOX2 Methylation has Higher Diagnostic Efficacy for Non-Small-Cell Lung Cancer.
Zeng S; Lin C; Huang Y
Mol Biotechnol; 2023 Jul; 65(7):1187-1197. PubMed ID: 36462101
[TBL] [Abstract][Full Text] [Related]
27. Correlation Between RASSF1A Gene Promoter Hypermethylation in Serum or Sputum and Non-Small Cell Lung Cancer (NSCLC): A Meta-Analysis.
Zhang Z; Yan S; Cui H; Chen H; Liu J
Med Sci Monit; 2019 Jul; 25():5518-5524. PubMed ID: 31342946
[TBL] [Abstract][Full Text] [Related]
28. Short stature homeobox 2 methylation as a potential noninvasive biomarker in bronchial aspirates for lung cancer diagnosis.
Ni S; Ye M; Huang T
Oncotarget; 2017 Sep; 8(37):61253-61263. PubMed ID: 28977861
[TBL] [Abstract][Full Text] [Related]
29. DNA Methylation Analysis of the
Zhang N; Liu Z; Li K; Xing X; Long C; Liu F; She B; Che N
J Oncol; 2023; 2023():5888844. PubMed ID: 36691467
[TBL] [Abstract][Full Text] [Related]
30. Promoter hypermethylation of
Branchi V; Schaefer P; Semaan A; Kania A; Lingohr P; Kalff JC; Schäfer N; Kristiansen G; Dietrich D; Matthaei H
Clin Epigenetics; 2016; 8():133. PubMed ID: 27999621
[TBL] [Abstract][Full Text] [Related]
31. DNA methylation of the homeobox genes PITX2 and SHOX2 predicts outcome in non-small-cell lung cancer patients.
Dietrich D; Hasinger O; Liebenberg V; Field JK; Kristiansen G; Soltermann A
Diagn Mol Pathol; 2012 Jun; 21(2):93-104. PubMed ID: 22555092
[TBL] [Abstract][Full Text] [Related]
32. Diagnosis of Lung Cancer by SHOX2 Gene Methylation Assay.
Song L; Yu H; Li Y
Mol Diagn Ther; 2015 Jun; 19(3):159-67. PubMed ID: 26014676
[TBL] [Abstract][Full Text] [Related]
33. A comprehensive diagnostic scheme of morphological combined molecular methylation under bronchoscopy.
Zhang J; Huang H; Yu F; Bian Y; Wang R; Liu H; Kang S; She B; Shi Z
Front Oncol; 2023; 13():1133675. PubMed ID: 37182143
[TBL] [Abstract][Full Text] [Related]
34. [Meta-analysis of the Association between RASSF1A Gene Promoter Methylation and Non-small Cell Lung Cancer].
Wei H; Fang N; Guo L; Wu Z; Zhou Q
Zhongguo Fei Ai Za Zhi; 2015 Jul; 18(7):443-50. PubMed ID: 26182870
[TBL] [Abstract][Full Text] [Related]
35. Assessment of SHOX2 methylation in EBUS-TBNA specimen improves accuracy in lung cancer staging.
Darwiche K; Zarogoulidis P; Baehner K; Welter S; Tetzner R; Wohlschlaeger J; Theegarten D; Nakajima T; Freitag L
Ann Oncol; 2013 Nov; 24(11):2866-70. PubMed ID: 24026539
[TBL] [Abstract][Full Text] [Related]
36. Diagnostic value of RASSF1A methylation for breast cancer: a meta-analysis.
Li M; Wang C; Yu B; Zhang X; Shi F; Liu X
Biosci Rep; 2019 Jun; 39(6):. PubMed ID: 31196964
[TBL] [Abstract][Full Text] [Related]
37. Promoter hypermethylation of the tumor-suppressor genes RASSF1A, GSTP1 and CDH1 in endometrial cancer.
Fiolka R; Zubor P; Janusicova V; Visnovsky J; Mendelova A; Kajo K; Lasabova Z; Plank L; Danko J
Oncol Rep; 2013 Dec; 30(6):2878-86. PubMed ID: 24068440
[TBL] [Abstract][Full Text] [Related]
38. Potentialities of aberrantly methylated circulating DNA for diagnostics and post-treatment follow-up of lung cancer patients.
Ponomaryova AA; Rykova EY; Cherdyntseva NV; Skvortsova TE; Dobrodeev AY; Zav'yalov AA; Bryzgalov LO; Tuzikov SA; Vlassov VV; Laktionov PP
Lung Cancer; 2013 Sep; 81(3):397-403. PubMed ID: 23806794
[TBL] [Abstract][Full Text] [Related]
39. Association of RASSF1A promoter methylation with lung cancer risk: a meta-analysis.
Huang YZ; Wu W; Wu K; Xu XN; Tang WR
Asian Pac J Cancer Prev; 2014; 15(23):10325-8. PubMed ID: 25556469
[TBL] [Abstract][Full Text] [Related]
40. Promoter methylation of RASSF1A and DAPK and mutations of K-ras, p53, and EGFR in lung tumors from smokers and never-smokers.
Liu Y; Gao W; Siegfried JM; Weissfeld JL; Luketich JD; Keohavong P
BMC Cancer; 2007 May; 7():74. PubMed ID: 17477876
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
